Kaitlyn D’Onofrio

DocwireNews

An article published in <a href="https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(20)30175-3/fulltext">The Lancet Oncology</a> assessed the effects of <a href="https://www.docwirenews.com/home-page-editor-picks/the-covid-19-pandemic-boris-johnson-in-intensive-care-senate-may-provide-more-help-for-small-businesses-and-more/">COVID-19</a> on <a href="https://www.docwirenews.com/docwire-pick/hem-onc-picks/five-facts-about-oncologist-dr-hahn-tapped-by-trump-to-head-fda/">oncology</a> around the world.&ldquo;As the coronavirus disease 2019 (COVID-19) pandemic escalates and countries struggle to contain the virus, health-care systems are under increasing pressure. Emergency departments and intensive care units are nearing breaking point, and medical resources are being diverted to tackle the crisis. Moreover, conferences are being cancelled, and research trials are grinding to a halt. So what does COVID-19 mean for patients with cancer, their physicians, and the wider oncology discipline?&rdquo; the article questions.Cancer patients are a high-risk population in the pandemic and have much more to lose if they sustain the virus&mdash;including worse complications and a greater mortality risk. Patients who do develop COVID-19 may have their cancer treatments delayed in the wake of treating the virus, although these decisions are made on a patient-by-patient basis. Quarantines are also preventing patients from making it to scheduled appointments and posing challenges when it comes to obtaining essential medicines.The effects of COVID-19 in the oncology sphere go beyond just patient repercussions and also affect research, education, and collaboration. University campuses have already closed down, with more following suit, switching to digital operations for the time being. While this works for learning and exams for students, practical lab work and field studies cannot operate in this fashion; some research projects have been suspended, and institutions will have to make difficult decisions as to which clinical trials will receive priority and which will be suspended in the midst of limited funding.At the time of the article&rsquo;s publishing, at least eight cancer-related conferences and meetings had also been cancelled, resulting in lost opportunities for collaboration and sharing the latest research. The societies and organizations that planned these meetings will also suffer significant financial losses as a result of the lost revenue from the cancelled meetings. Smaller societies that rely on income generated through meetings and related activities may be compromised entirely.Given that the pandemic poses constant changes, it is difficult to predict its long-term effects. The article concludes by saying, &ldquo;Ultimately, the situation might lead to substantial changes in how research and medicine are practiced in the future, such as reduced international travel and increased remote networking and telemedicine. Until the COVID-19 pandemic is over, we can only hope that the consequences are not too devastating for patients and that the oncology community and beyond are able to weather this unprecedented storm.&rdquo;

Jordana Jampel

Positive Preliminary Results From Phase 1 Trial of Dopaminergic Neuron Graft for Parkinson’s Disease

Dementia

Bradley Warady, MD

Joel M. Topf, MD, FACP

2025 Hume Award Winner Is Dedicated to Children’s Care

NKF Spring Clinical Meetings 2025

Distant Brain Metastases in Cutaneous Melanoma May Be Mitigated With Multiple Pathway Inhibitors

Melanoma

Latest News

Here’s How COVID-19 Is Affecting Oncology On a Global Scale

COVID-19

An article published in The Lancet Oncology assessed the effects of COVID-19 on oncology around the world. ...

About Us

Editorial Policy

Advertising

Contact Us

eNewsletters

Contribute

Career Center

MashupMD

Blood Cancers Today

Cancer Nursing Today

GU Oncology Now

Urban Health Today

Bile Duct Cancer

Colorectal Cancer

Gastroesophageal Cancer

Gastric Cancer

GEP-NETs

GIST

Liver Cancer

Pancreatic Cancer

GI Oncology Now

Anemia

Deep Vein Thrombosis

Essential Thrombocythemia

Hemophilia

Immune Thrombocytopenic Purpura

Myelodysplastic Syndromes

Myelofibrosis

Myeloproliferative Neoplasms

Polycythemia Vera

Pulmonary Embolism

Sickle Cell Disease

Thrombocytopenia

Thrombophilia

Thrombosis

Thrombotic Thrombocytopenic Purpura

Venous Thromboembolism

von Willebrand Disease

Heme Today

Acute Kidney Injury

ADPKD

Anemia and Kidney Disease

Chronic Kidney Disease

COVID-19 and Kidney Disease

Diabetes and Hypertension

End-Stage Renal Disease

Gout

Hyperkalemia

IgAN

Kidney Transplantation

Metabolic Acidosis

Nephrology Times

HER2 Breast Cancer

HR Breast Cancer

Triple-Negative Breast Cancer

Genetics & Breast Cancer

Breast Cancers Today

Atherosclerotic Disease

Atrial Fibrillation

Heart Failure

Hypertension

Interventional Cardiology

Lipid Management

Practice Tips With Dr. Lichaa

Preventive Cardiology

Stroke

Cardiology

Breast Cancer

Gynecologic Cancer

Head and Neck Cancer

Skin Cancer

Oncology

Sleep

Urology

Diabetes

Ophthalmology

— Demodex Blepharitis

Neurology

Rheumatology

Gastroenterology

Pulmonology

Infectious Diseases

— HIV

Health and Wellness

Lupus

Future of Medicine

Orthopedics

Pharmacology

Career News

More

Conferences

CardioNerds

The Sleep Source With Dr. Morse

Rheumatology Rounds With Dr. Maheswaranathan

Partners

Expert Interviews

Subscribe